AZ's tozorakimab delivers COPD benefit across populations in Phase 3
AstraZeneca's anti-IL-33 antibody tozorakimab posted positive Phase 3 results in COPD (Oberon and Titania), reducing the annualized rate of moderate-to-severe exacerbations versus placebo in former smokers and showing benefit across the overall population, with a favorable safety profile. The drug’s supposed differentiation comes from complete inhibition of ST2 and RAGE/EGFR signaling, unlike rivals Roche and Sanofi/Regeneron’s IL-33 blockers that produced mixed results. AZ plans to present full data at an upcoming meeting and is pursuing two additional Phase 3 trials (Prospero, Miranda), while maintaining a target of potentially $3–5 billion in peak sales if approved.